8-K
filed November 10, 2022, 6:59 PM ET
ticker XRAY
CIK 0000818479
other material
confidence high
sentiment negative
materiality 0.80
Dentsply Sirona obtains lender consents to extend reporting deadlines; plans restatement of 2021 financials
DENTSPLY SIRONA Inc.
- Obtained consent to extend delivery of Q2 2022 financials to Nov 14; delivered on Nov 9, 2022.
- Entered consent agreements for note purchase agreements extending deadlines for Q1 2022, Q2 2022, and restated 2021 financials.
- Acknowledges intent to restate Q3 2021 and annual 2021 financial statements.
- Failure to deliver by extended deadline would constitute immediate event of default; company has now delivered.
- As of Nov 9, 2022, delivered Q1, Q2 2022 and restated 2021 financials to lenders and noteholders.
Key facts
Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
DENTSPLY SIRONA Inc. amended Note Purchase and Guarantee Agreement Amendment No. 2 and Consent with Sirona Dental Services GmbH and the noteholders with respect to the Note Purchase Agreement and Guarantee Agreement, dated as of October 27, 2016 (effective 2022-11-05).
- Action
- amendment
- Agreement
- notes offering
- Counterparty
- Sirona Dental Services GmbH and the noteholders with respect to the Note Purchase Agreement and Guarantee Agreement, dated as of October 27, 2016
- Effective
- 2022-11-05
Exact text from the filing
b. Note Purchase and Guarantee Agreement Amendment No. 2 and Consent, dated as of November 5, 2022, by and among the Company, Sirona Dental Services GmbH and the noteholders with respect to the Note Purchase Agreement and Guarantee Agreement, dated as of October 27, 2016
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
DENTSPLY SIRONA Inc. amended Note Purchase Agreement Amendment No. 2 and Consent with the noteholders with respect to the Note Purchase Agreement, dated as of June 24, 2019 (effective 2022-11-05).
- Action
- amendment
- Agreement
- notes offering
- Counterparty
- the noteholders with respect to the Note Purchase Agreement, dated as of June 24, 2019
- Effective
- 2022-11-05
Exact text from the filing
c. Note Purchase Agreement Amendment No. 2 and Consent, dated as of November 5, 2022, by and among the Company and the noteholders with respect to the Note Purchase Agreement, dated as of June 24, 2019
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
DENTSPLY SIRONA Inc. amended Note Purchase Agreement Amendment No. 2 and Consent with the noteholders with respect to the Note Purchase Agreement, dated as of December 11, 2015 (effective 2022-11-05).
- Action
- amendment
- Agreement
- notes offering
- Counterparty
- the noteholders with respect to the Note Purchase Agreement, dated as of December 11, 2015
- Effective
- 2022-11-05
Exact text from the filing
On November 5, 2022, the Company entered into the following agreements (collectively, the “Consent Agreements”): a. Note Purchase Agreement Amendment No. 2 and Consent, dated as of November 5, 2022, by and among the Company and the noteholders with respect to the Note Purchase Agreement, dated as of December 11, 2015
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
DENTSPLY SIRONA Inc. amended Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent (effective 2022-11-04).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- JPMorgan Chase Bank, N.A., as administrative agent
- Effective
- 2022-11-04
Exact text from the filing
On November 4, 2022, DENTSPLY SIRONA Inc. (the “Company”) obtained the consent of the requisite lenders under its revolving credit facility, dated July 27, 2018, with JPMorgan Chase Bank, N.A., as administrative agent (the “Credit Agreement”), to further extend the time period for delivery of the Company’s unaudited financial statements for the fiscal quarter ended June 30, 2022
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.